Altimmune, Inc. (ALT)
4.57
+0.05
(+1.11%)
USD |
NASDAQ |
Feb 24, 16:00
4.53
-0.04
(-0.88%)
After-Hours: 20:00
Altimmune Research and Development Expense (Quarterly) : 14.93M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| CorMedix, Inc. | 5.098M |
| Actinium Pharmaceuticals, Inc. | 4.042M |
| Aldeyra Therapeutics, Inc. | 5.431M |
| Viking Therapeutics, Inc. | 153.46M |
| Seres Therapeutics, Inc. | 12.62M |